Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of September 2024, specifically dated September 9, 2024. Haleon Plc, a global leader in consumer health with brands such as Advil, Sensodyne, and Panadol, filed this report to announce a corporate action regarding its debt financing program.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, or liquidity for the reporting period. The document focuses exclusively on the publication of a supplement to the company's Euro Medium Term Note (EMTN) Programme.
Material Changes
The primary material event is the publication of a supplement to the Base Listing Particulars dated May 3, 2024. This supplement relates to the £10,000,000,000 Euro Medium Term Note Programme issued by Haleon UK Capital plc and Haleon Netherlands Capital B.V., which is guaranteed by Haleon Plc.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on operational outlook, or discussion of specific risks or contingencies. It includes a standard disclaimer stating that the information in the Base Listing Particulars is targeted at residents of specific countries and should not be relied upon by persons outside those jurisdictions without verification.
Key Facts for Investor Verification
- Verify the specific details of the supplement to the EMTN Programme by accessing the Base Listing Particulars and Supplement at www.haleon.com/investors/debt-investors.
- Confirm eligibility to rely on the information contained in the Base Listing Particulars based on residency requirements outlined in the document.
- Note that this filing does not contain updated financial performance data for the third quarter of 2024.